Icaritin is a monomer compound with a content of 98.0%~102.0% obtained by enzymatic hydrolysis from the Chinese herbal medicine Epimedium. It is a natural isopentenyl flavonoid compound that can inhibit the occurrence and development of IL-6-mediated LNCaP cell line and TRAMP mouse neuroendocrine prostate cancer. The following conclusions were issued on September 25th and obtained by the Chinese Society of Clinical Oncology (CSCO) in 2021.
|Median OS data of enriched population|
The results of this study showed that in the enriched population, the median OS of the Icaritin group was significantly better than that of the control group: 13.54 months vs. 6.87 months (HR=0.43, p=0.0092).
|OS data in PD patients|
Icaritin is also one of our main products. We are very happy to hear this news. So notify you as soon as possible. Once the product is on the market, it will bring good news to cancer patients. If you want to know more about this product, you are welcome to consult.
The above data information is referenced from （http://www.shenogen.com/newsdetail.aspx?NewsId=190&cateid=25）